INTRODUCTION: Vascularized composite allotransplantation (VCA), a new reconstructive option for @entity1 suffering from extensive @entity154 leads to superior functional and aesthetic outcomes compared to the standard autologous reconstruction. Among VCA recipients, each case involves different facial structures and tissues depending on the @entity1 's injury, thus drawing conclusions on the mechanism of immune interactions between the donor and recipient is challenging. This study introduces a new total hemiface VCA model, including scalp, external ear, @entity11383 , premaxilla, upper/lower lids, nose, and upper/lower lips to evaluate the effect of transplantation of multitissue VCA on the recipient's immune response. MATERIAL AND METHODS: Ten hemiface allotransplantations were performed in two groups between Lewis-Lewis (isograft) and LBN-Lewis (allograft) @entity35 . @entity205 ( @entity9472 ) monotherapy was applied in the allograft group to prevent rejection. RESULTS: All flaps survived up to 100 days post-transplant. The mean warm @entity63 time was 45 minutes. Histological analysis revealed normal bone, cartilage (ear and nose), conjunctiva, palpebra, and eyelashes. Flow cytometry confirmed donor-specific chimerism for T cells ( @entity11264 /RT1(n) and CD8/RT1(n) ) and B cells (CD45RA/RT1(n) ) in the peripheral blood of all @entity35 in the allotransplantation group. At post-transplant day 7, chimerism levels were at 1.68% for @entity11264 /RT1(n) , 0.46% for CD8/RT1(n) and 0.64% for CD45RA/RT1(n) . However, chimerism levels for @entity11264 /RT1(n) , CD8/RT1(n) , and CD45RA/RT1(n) populations decreased at long-term follow-up (at post-transplant day 100) to 0.08%, 0.04%, and 0.23%, respectively. CONCLUSION: The feasibility and long-term survival of the new hemiface VCA transplantation model was confirmed, donor-specific chimerism and post-transplant tissue changes were evaluated.    2016 Wiley Periodicals, Inc. Microsurgery, 2016.

A new total hemiface allotransplantation model in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity154 :: ('MESH:D000013', 'Disease') :: ['facial defects'] @entity9472 :: ('D016572', 'Chemical') :: ['CsA'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia'] @entity11264 :: ('24932(Tax:10116)', 'Gene') :: ['CD4'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['Cyclosporine A'] @entity11383 :: ('MESH:C567780', 'Disease') :: ['mystacial pad'] @entity35 :: ('10116', 'Species') :: ['rats']
@entity35 :: (10116,Species) :: ['rats']
